Latest Headlines

Latest Headlines

Cytomedix shutters R&D site after PhII failure

Shares of the penny stock biotech slid after the news was released.

Cytomedix snaps up stem cell biotech Aldagen for a bargain price

Just 10 months after abandoning its second effort to go public, Aldagen is selling out to a small regenerative medicine company for just $16 million in shares and the chance to earn another chunk of

Cytomedix gets $13M in RDO

Cytomedix says it has landed approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements. The company is